芦可替尼：治疗骨髓纤维化患者的一种有效且选择性的 Janus 激酶 1 和 2 抑制剂。临床医生的最新资讯。
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.
机构信息
Guy's and St Thomas's NHS Foundation Trust, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.
出版信息
Ther Adv Hematol. 2012 Dec;3(6):341-54. doi: 10.1177/2040620712459746.
Abstract
Ruxolitinib became the first US Food and Drug Administration approved therapy for myelofibrosis in 2011 and EU approval is anticipated in summer 2012. Two large phase III trials (known as the COMFORT studies) were the basis for this approval and were published recently. In this review article we discuss the challenges in managing myelofibrosis, the information to date about ruxolitinib and speculate as to the future direction with this and similar agents.
摘要
芦可替尼于 2011 年成为首个获得美国食品和药物管理局批准用于治疗骨髓纤维化的药物，预计 2012 年夏季将在欧盟获得批准。两项大型 III 期临床试验（称为 COMFORT 研究）是该批准的基础，并于近期发表。在这篇综述文章中，我们讨论了骨髓纤维化的治疗挑战，以及迄今为止关于芦可替尼的信息，并对该药和类似药物的未来方向进行了推测。
相似文献
1
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.
Ther Adv Hematol. 2012 Dec;3(6):341-54. doi: 10.1177/2040620712459746.
2
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
Clin Cancer Res. 2012 Jun 15;18(12):3212-7. doi: 10.1158/1078-0432.CCR-12-0653. Epub 2012 Apr 27.
3
Ruxolitinib: a review of its use in patients with myelofibrosis.
Drugs. 2015 Feb;75(3):297-308. doi: 10.1007/s40265-015-0351-8.
4
Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Leuk Lymphoma. 2023 Jun;64(6):1063-1081. doi: 10.1080/10428194.2023.2196593. Epub 2023 Apr 20.
5
Clarifying the use of ruxolitinib in patients with myelofibrosis.
Oncology (Williston Park). 2013 Jul;27(7):706-14.
6
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
J Hematol Oncol. 2023 Jul 27;16(1):82. doi: 10.1186/s13045-023-01471-z.
7
Ruxolitinib for myelofibrosis--an update of its clinical effects.
Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):638-45. doi: 10.1016/j.clml.2013.09.006. Epub 2013 Oct 2.
8
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.
9
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
Cochrane Database Syst Rev. 2015 Apr 10;2015(4):CD010298. doi: 10.1002/14651858.CD010298.pub2.
10
Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib.
Expert Rev Hematol. 2022 Jul;15(7):583-595. doi: 10.1080/17474086.2022.2098105. Epub 2022 Jul 11.
引用本文的文献
1
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations.
Cancers (Basel). 2024 Dec 8;16(23):4113. doi: 10.3390/cancers16234113.
2
Trans-vaccenic acid reprograms CD8 T cells and anti-tumour immunity.
Nature. 2023 Nov;623(7989):1034-1043. doi: 10.1038/s41586-023-06749-3. Epub 2023 Nov 22.
3
Lupus Nephritis: New and Emerging Biologic and Targeted Therapies.
BioDrugs. 2023 Jul;37(4):463-475. doi: 10.1007/s40259-023-00597-3. Epub 2023 Apr 24.
4
New approaches to tackle cytopenic myelofibrosis.
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):235-244. doi: 10.1182/hematology.2022000340.
5
Immune response and possible therapeutics in COVID-19.
RSC Adv. 2021 Jan 4;11(2):960-977. doi: 10.1039/d0ra08901j. eCollection 2020 Dec 24.
6
A screen of repurposed drugs identifies AMHR2/MISR2 agonists as potential contraceptives.
Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2122512119. doi: 10.1073/pnas.2122512119. Epub 2022 Apr 5.
7
Ruxolitinib ameliorates progressive anemia and improves survival during episodes of emergency granulopoiesis in Fanconi C mice.
Exp Hematol. 2022 May;109:55-67.e2. doi: 10.1016/j.exphem.2022.03.001. Epub 2022 Mar 9.
8
Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2-induced myeloproliferative neoplasms.
Blood Cancer J. 2022 Mar 7;12(3):37. doi: 10.1038/s41408-022-00628-2.
9
Structural Basis of Inhibition of DCLK1 by Ruxolitinib.
Int J Mol Sci. 2021 Aug 6;22(16):8488. doi: 10.3390/ijms22168488.
10
Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.
J Control Release. 2021 Sep 10;337:258-284. doi: 10.1016/j.jconrel.2021.07.028. Epub 2021 Jul 20.
本文引用的文献
1
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
Br J Haematol. 2013 Aug;162(3):326-35. doi: 10.1111/bjh.12384. Epub 2013 May 23.
2
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Blood. 2012 Aug 9;120(6):1202-9. doi: 10.1182/blood-2012-02-414631. Epub 2012 Jun 20.
3
Allogeneic stem cell transplantation for myelofibrosis in 2012.
Br J Haematol. 2012 May;157(4):413-25. doi: 10.1111/j.1365-2141.2012.09107.x. Epub 2012 Mar 29.
4
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Blood. 2012 May 17;119(20):4614-8. doi: 10.1182/blood-2011-12-400051. Epub 2012 Mar 15.
5
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.
6
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.
7
Long-term outcome of treatment with ruxolitinib in myelofibrosis.
N Engl J Med. 2011 Oct 13;365(15):1455-7. doi: 10.1056/NEJMc1109555.
8
Possible new LNK mutations in myeloproliferative neoplasms.
Am J Hematol. 2011 Oct;86(10):866-8. doi: 10.1002/ajh.22107. Epub 2011 Aug 22.
9
EZH2 mutational status predicts poor survival in myelofibrosis.
Blood. 2011 Nov 10;118(19):5227-34. doi: 10.1182/blood-2011-06-363424. Epub 2011 Sep 14.
10
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Blood. 2011 Aug 25;118(8):2069-76. doi: 10.1182/blood-2011-01-330563. Epub 2011 Jul 1.
Zotero 插件